1. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J. Am. Stat. Assoc. 1996;91:444–55.
2. Ayanlowo A, Redden D. A two-stage conditional power adaptive design adjusting for treatment by covariate interaction. Contemp. Clin. Trials. 2008;29:428–38. [PubMed]
3. Barnard J, Frangakis CE, Hill JL, Rubin DB. Principal stratification approach to broken randomized experiments: a case study of school choice vouchers in New York City/Comment/Rejoinder. J. Am. Stat. Assoc. 2003;98:299–323.
4. Bartlett RH, Gazzaniga AB, Jefferies MR, Huxtable RF, Haiduc NJ, Fong SW. Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans. Am. Soc. Artif. Intern. Organs. 1976;22:80–93. [PubMed] 5. Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics. 1985;76:479–87. [PubMed]
6. Begg CB. Investigating therapies of potentially great benefit: ECMO: Comment. Stat. Sci. 1989;4:320–22.
7. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics. 2005;61:343–54. [PubMed] 8. Bennett CC, Johnson A, Field DJ, Elbourne D., U. K. Collab. ECMO Trial Group UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet. 2001;357:1094–96. [PubMed] 9. Berger V, Rezvania A, Makarewicz V. Direct effect on validity of response run-in selection in clinical trials. Control. Clin. Trials. 2003;24:156–66. [PubMed]
10. Berry D. Adaptive trials and Bayesian statistics in drug development. Biopharm. Rep. 2001;9:1–11.
11. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Stat. Sci. 2004;19:175–87.
12. Berry DA, Mueller P, Grieve A, Smith M, Parke T, et al. Adaptive Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Carlin B, Carriiquiry A, editors. Case Studies in Bayesian Statistics. Springer; New York: 2002. p. xiv.p. 376.
13. Bhaumik D, Roy A, Aryal S, Hur K, Duan N, et al. Sample size determination for studies with repeated continuous outcomes. Psychiatr. Ann. 2009 In press.
14. Bloom H. Accounting for no-shows in experimental evaluation designs. Eval. Rev. 1984;8:225–46.
15. Boekeloo B, Griffin M. Review of clinical trials testing the effectiveness of physician approaches to improving alcohol education and counseling in adolescent outpatients. Curr. Pediatr. Rev. 2007;3:93–101.
16. Boruch B, Foley E, Grimshaw J. Estimating the effects of interventions in multiple sites and settings: place-based randomized trials. Socialvetenskaplig Tidskr. 2002;2–3:221–39.
17. Braver SL, Smith MC. Maximizing both external and internal validity in longitudinal true experiments with voluntary treatments: the “combined modified” design. Eval. Progr. Plann. 1996;19:287–300.
18. Brooner RK, Kidorf MS, King VL, Stoller KB, Neufeld KJ, Kolodner K. Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. Drug Alcohol Depend. 2007;88(Suppl 2):S14–23. [PMC free article] [PubMed] 19. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med. Res. Methodol. 2006;8:54. [PMC free article] [PubMed] 20. Brown CH. Comparison of mediational selected strategies and sequential designs for preventive trials: comments on a proposal by Pillow et al. Am. J. Community Psychol. 1991;19:837–46. [PubMed]
21. Brown CH, Faraone SV. Prevention of schizophrenia and psychotic behavior: definitions and methodologic issues. In: Stone WS, Faraone SV, Tsuang MT, editors. Early Clinical Intervention and Prevention in Schizophrenia. Humana; Totowa, NJ: 2004. pp. 255–84.
22. Brown CH, Indurkhya A, Kellam SG. Power calculations for data missing by design with application to a follow-up study of exposure and attention. J. Am. Stat. Assoc. 2000;95:383–95.
23. Brown CH, Wang W, Kellam SG, Muthén BO, Petras H, et al. Methods for testing theory and evaluating impact in randomized field trials: Intent-to-treat analyses for integrating the perspectives of person, place, and time. Drug Alcohol Depend. 2008;95:S74–104. Supplementary data, doi:10.1016/j.drugalcdep.2008.01.005. [PMC free article] [PubMed] 24. Brown CH, Wyman PA, Brinales JM, Gibbons RD. The role of randomized trials in testing interventions for the prevention of youth suicide. Int. Rev. Psychiatry. 2007;19:617–31. [PubMed] 25. Brown CH, Wyman PA, Guo J, Peña J. Dynamic wait-listed designs for randomized trials: new designs for prevention of youth suicide. Clin. Trials. 2006;3:259–71. [PubMed] 26. Bruce M, Ten Have T, Reynolds C, Katz II, Schulberg HC, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients. JAMA. 2004;291:1081–91. [PubMed] 27. Campbell F, Ramey C. Effects of early intervention on intellectual and academic achievement: a follow-up study of children from low-income families program title: Carolina Abecedarian Project. Child Dev. 1994;65:684–98. [PubMed]
28. Chamberlain P. Treating Chronic Juvenile Offenders: Advances Made Through the Oregon Multidimensional Treatment Foster Care Model. Am. Psychol. Assoc.; Washington, DC: 2003. p. xvi.p. 186. ill.; 26 cm.
29. Chamberlain P, Brown CH, Saldana L, Reid J, Wang W. Engaging and recruiting counties in an experiment on implementing evidence-based practice in California. Administration and Policy in Mental Health and Mental Health Services Research. 2008;35:250–60. [PMC free article] [PubMed] 30. Chappell R, Karrison T, Chappell R, Karrison T. Continuous Bayesian adaptive randomization based on event times with covariates by Cheung et al. Statistics in Medicine 2006. 2007;25:55–70. [PubMed]Stat. Med. 26:3050–2. author reply pp. 2–4. [PubMed] 31. Chow S-C, Lu Q, Tse S-K. Statistical analysis for two-stage seamless design with different study endpoints. J. Biopharm. Stat. 2007;17:1163–76. [PubMed]
32. Cialdini R. Influence: Science and Practice. Allyn & Bacon; Needham Heights, MA: 2001.
33. Collins LM, Murphy SA, Bierman KA. A conceptual framework for adaptive preventive interventions. Prev. Sci. 2004;5:185–96. [PMC free article] [PubMed] 34. Collins LM, Murphy S, Nair V, Strecher V. A strategy for optimizing and evaluating behavioral interventions. Ann. Behav. Med. 2005;30:65–73. [PubMed] 35. Collins LM, Murphy S, Stecher V. The Multiphase Optimization Strategy (MOST) and the Sequential Assignment Randomized Trial (SMART): new methods for more potent eHealth interventions. Am. J. Prevent. Med. 2007;32:S112–S18. [PMC free article] [PubMed] 36. Dexter P, Wolinsky F, Gramelspacher G, Zhou X, Eckert G, et al. Effectiveness of computer-generated reminders for increasing discussions about advance directives and completion of advance directive forms: a randomized, controlled trial. Ann. Intern. Med. 1998;128:102–10. [PubMed]
37. Dolan LJ, Kellam SG, Brown CH, Werthamer-Larsson L, Rebok GW, et al. The short-term impact of two classroom-based preventive interventions on aggressive and shy behaviors and poor achievement. J. Appl. Dev. Psychol. 1993;14:317–45.
38. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. Arnold; London: 2000.
39. Donner A, Klar N. Pitfalls of and controversies in cluster randomized trials. Am. J. Public Health. 2004;94:416–22. [PubMed]
40. Dragalin V. Adaptive designs: terminology and classification. Drug Inf. J. 2006;40:425–35.
41. Dragalin V, Fedorov VV. Rep. GSK BDS Tech. Rep. 2004–02. GlaxoSmithKlein Pharma.; Collegeville, Penn.: 2004. Adaptive model-based designs for dose-finding studies.
42. Dragalin V, Hsuan F, Padmanabhan SK. Adaptive designs for dose-finding studies based on Sigmoid Emax Model. J. Biopharm. Stat. 2007;17:1051–70. [PubMed]
43. Duan N, Wells K, Braslow J, Weisz J. Randomized encouragement trial: a paradigm for public health intervention evaluation. Rand Corp.; 2002. Unpublished manuscript.
44. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch. Int. Med. 2003;163(17):2006–10. [PubMed] 45. Ekström E, Hyder S, Chowdhury M. Efficacy and trial effectiveness of weekly and daily iron supplementation among pregnant women in rural Bangladesh: disentangling the issues. Am. J. Clin. Nutr. 2002;76:1392–400. [PubMed] 46. Erickson SJ, Gerstle M, Feldstein SW. Brief interventions and motivational interviewing with children, adolescents, and their parents in pediatric health care settings: a review. Arch. Pediatr. Adolesc. Med. 2005;159:1173–80. [PubMed]
47. Fisher R. The Design of Experiments. Oliver & Boyd; Edinburgh: 1935.
48. Frangakis CE, Brookmeyer RS, Varadham R, Safaeian M, Vlahov D, Strathdee SA. Methodology for evaluating a partially controlled longitudinal treatment using principal stratification, with application to a needle exchange program. J. Am. Stat. Assoc. 2004;99:239–50.
49. Frangakis CE, Rubin DB. Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika. 1999;86:365–79.
50. Frangakis CE, Rubin DB, Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58:21–29. [PubMed] 51. Frangakis CE, Rubin DB, Zhou XH. Clustered encouragement designs with individual noncompliance: Bayesian inference with randomization, and application to advance directive forms. Biostatistics. 2002;3:147–64. [PubMed] 52. Freedman B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 1987;317:141–45. [PubMed] 53. Freedman DA. Statistical models for causation. What inferential leverage do they provide? Eval. Rev. 2006;30:691–713. [PubMed] 54. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, et al. Adaptive designs in clinical drug development—an executive summary of the PhRMA working group. J. Biopharm. Stat. 2006;16:275–83. discussion 85–91. [PubMed]
55. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive design in clinical research: issues, opportunities, and recommendations—Rejoinder. J. Biopharm. Stat. 2006;16:311–12.
56. Glasgow R, Vogt T, Boles S. Evaluating the public health impact of health promotion interventions: The RE-AIM framework. Am. J. Public Health. 1999;89:1323–27. [PubMed] 57. Goetghebeur E, Vansteelandt S. Discussion of ‘Clustered encouragement designs with individual noncompliance: Bayesian inference with randomization, and application to advance directive forms’ by Frangakis, Rubin and Zhou. Biostatistics. 2002;3:169–71. [PubMed]
58. Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE, editors. Reducing Suicide: A National Imperative. Natl. Acad. Press; Washington, DC: 2002. p. 496.
59. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control. Clin. Trials. 1994;15:450–62. [PubMed] 60. Gould L. Sample-size re-estimation: recent developments and practical considerations. Stat. Med. 2001;20:2625–43. [PubMed] 61. Gould MS. Suicide and the media. Ann. N. Y. Acad. Sci. 2001;932:200–21. discussion 21–24. [PubMed] 62. Gould MS, Greenberg T, Velting DM, Shaffer D. Youth suicide risk and preventive interventions: a review of the past 10 years. J. Am. Acad. Child Adolesc. Psychiatry. 2003;42:386–405. [PubMed] 63. Gould MS, Petrie K, Kleinman MH, Wallenstein S. Clustering of attempted suicide: New Zealand national data. Int. J. Epidemiol. 1994;23:1185–89. [PubMed] 64. Gould MS, Wallenstein S, Kleinman M. Time-space clustering of teenage suicide. Am. J. Epidemiol. 1990;131:71–78. [PubMed]
65. Hahn J, Hirano K, Karlan D. Adaptive design of multiple stage experiments using the propensity score. Univ. Munich.; 2007. Unpublished manuscript.
66. Hill A. Principles of Medical Statistics. Lancet; London: 1961.
67. Hill ABS. Statistical Methods in Clinical and Preventive Medicine. Livingstone; Edinburgh /London: 1962. p. viii.p. 610.p. 8. plates.
68. Hirano K, Imbens G, Rubin D, Zhou X. Assessing the effect of an influenza vaccine in an encouragement design. Biostatistics. 2000;1:69–88. [PubMed] 69. Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58:823–31. [PubMed]
70. Jin H, Rubin DB. Principal stratification for causal inference with extended partial compliance. Application to Efron-Feldman data. J. Am. Statist. Assoc. 2008;103:101–11.
71. Jo B. Estimation of intervention effects with noncompliance: alternative model specifications. J. Educ. Behav. Stat. 2002;27:385–409.
72. Jo B. Model misspecification sensitivity analysis in estimating causal effects of interventions with noncompliance. Stat. Med. 2002;21:3161–81. [PubMed] 73. Jo B. Statistical power in randomized intervention studies with noncompliance. Psychol. Methods. 2002;7:178–93. [PubMed] 74. Jo B, Asparouhov T, Muthén BO, Ialongo NS, Brown CH, et al. Cluster randomized trials with treatment noncompliance. Psychol. Methods. 2008;13:1–18. [PMC free article] [PubMed]
75. Jo B, Muthén B. Longitudinal studies with intervention and noncompliance: estimation of causal effects in growth mixture modeling. In: Duan N, Reise S, editors. Multilevel Modeling: Methodological Advances, Issues, and Applications. Erlbaum; Mahwah, NJ: 2003. pp. 112–39.
76. Jo B, Muthén BO. Modeling of intervention effects with noncompliance: a latent variable approach for randomized trials. In: Marcoulides GA, Schumacker RE, editors. New Developments and Techniques in Structural Equation Modeling. Erlbaum; Hillsdale, NJ: 2001. pp. 57–87.
77. Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control. Clin. Trials. 2003;24:506–22. [PubMed] 78. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch. Gen. Psychiatry. 2006;63:484–89. [PubMed] 79. Krams M, Burman C-F, Dragalin V, Gaydos B, Grieve AP, et al. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop. J. Biopharm. Stat. 2007;17:957–64. [PubMed] 80. Lake S, Kammann E, Klar N, Betensky R. Sample size re-estimation in cluster randomization trials. Stat. Med. 2002;21:1337–50. [PubMed] 81. Lang J. The use of a run-in to enhance compliance. Stat. Med. 1990;9:87–95. [PubMed] 82. Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin. Trials. 1:9–20. [PubMed] 83. Lee S, Walker J, Jakul L, Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress. Anxiety. 2004;19:10–19. [PubMed]
84. Lind J. A Treatise of the Scurvy in Three Parts. Containing an Inquiry into the Nature, Causes and Cure of that Disease, Together with a Critical and Chronological View of What Has Been Published on the Subject. Millar; London: 1753.
85. Liu Q, Pledger G. Phase 2 and 3 combination designs to accelerate drug development. J. Am. Stat. Assoc. 2005;100:493–502.
86. Lossius MI, Hessen E, Mowinckel P, Stavem K, Erikssen J, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia. 2008;49:455–63. [PubMed] 87. McDonald C, Hiu S, Tierney W. Effects of computer reminders for influenza vaccination on morbidity during influenza epidemics. MD Comput. 1992;9:304–12. [PubMed]
88. Mehta C, Tsiatis A. Flexible sample size considerations using information based interim monitoring. Drug Inf. J. 2001;35:1095–112.
89. Merrell KW, Buchanan R. Intervention selection in school-based practice: using public health models to enhance systems capacity of schools. Sch. Psychol. Rev. 2006;35:167–80.
90. Mrazek PJ, Haggerty RJ. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Natl. Acad. Sci., Inst. Med.; Washington, DC: 1994.
91. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst. Rev. 2008;3:CD001340. [PubMed] 92. Muñoz R, Lenert L, Delucci K, Stoddart J, Perez J, et al. Toward evidence-based Internet interventions: a Spanish/English site for international smoking cessation trials. Nicotine Tob. Res. 2006;8:77–87. [PubMed] 93. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat. Med. 2005;24:1455–81. [PubMed] 94. Murphy SA, Lynch KG, Oslin D, McKay JR, Ten Have T. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007;88:S24–30. [PMC free article] [PubMed]
95. Murray DM. Monogr. Epidemiol. Biostat. Oxford Univ. Press; New York: 1998. Design and Analysis of Group-Randomized Trials.
96. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–76. [PubMed]
97. Muthén BO, Brown CH, Leuchter A, Hunter A. General approaches to analysis of course: applying growth mixture modeling to randomized trials of depression medication. In: Shrout PE, editor. Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures. Am. Psychiatr.; Washington, DC: 2008. In press.
98. Muthén BO, Brown CH, Masyn K, Jo B, Khoo ST, et al. General growth mixture modeling for randomized preventive interventions. Biostatistics. 2002;3:459–75. [PubMed]
99. Muthén BO, Jo B, Brown CH. Comment on the Barnard, Frangakis, Hill & Rubin article, “Principal stratification approach to broken randomized experiments: a case study of school choice vouchers in New York City.” J. Am. Stat. Assoc. 2003;98:311–14.
100. Nair V, Strecher V, Fagerlin P, Resnicow K, Murphy S, et al. Screening experiments and the use of fractional factorial designs in behavioral intervention research. Am. J. Public Health. 2008;98:1354–59. [PMC free article] [PubMed]
101. Natl. Comm. for the Prot. of Hum. Subjects Biomed. and Behav. Res. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Dep. Health Educ. Welfare; Washington, DC: 1979.
102. O' Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46:33–48. [PubMed] 103. O'Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, et al. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics. 1989;84:957–63. [PubMed] 104. Pablos-Mendez A, Barr R, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279:222–25. [PubMed] 105. Perry C, Bishop D, Taylor G, Davis M, Story M, et al. A randomized school trial of environmental strategies to encourage fruit and vegetable consumption among children. Health Educ. Behav. 2004;31:65–76. [PubMed] 106. Pillow DR, Sandler IN, Braver SL, Wolchik SA, Gersten JC, et al. Theory-based screening for prevention: focusing on mediating processes in children of divorce. Am. J. Community Psychol. 1991;19:809–36. [PubMed]
107. Pocock SJ. Clinical trials: A Practical Approach. Wiley; New York: 1983.
108. Proschan MA. Two-stage sample size re-estimation based on a nuisance parameter: a review. J. Biopharm. Stat. 2005;15:559–74. [PubMed] 109. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New Engl. J. Med. 2005;352:1293–304. [PubMed]
110. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
111. Roy A, Bhaumik D, Aryal S, Gibbons R. Sample size determination for hierarchical longitudinal designs with differential attrition rates. Biometrics. 2007;63:699–707. [PubMed]
112. Royall R. Investigating therapies of potentially great benefit: ECMO: Comment. Stat. Sci. 1989;4:318–19.
113. Royall RM. Ethics and statistics in randomized clinical trials: Rejoinder. Stat. Sci. 1991;6:83–88. [PubMed] 114. Sandler I, Ostrom A, Bitner M, Ayers T, Wolchik S, Daniels V. Developing effective prevention services for the real world: a prevention service development model. Am. J. Commun. Psychol. 2005;35:127–42. [PubMed] 115. Sheiner L, Rubin D. Intention to treat analysis and the goals of clinical trials. Clin. Pharmacol. Ther. 1995;57:6–15. [PubMed] 116. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics. 1999;55:190–97. [PubMed] 117. Smith-Daniels V, Sandler I, Wolchik S. Use of quality management methods in the transition from efficacious prevention programs to effective prevention services. Am. J. Community Psychol. 2008;41:250–61. [PubMed] 118. Sommer A, Zeger S. On estimating efficacy from clinical trials. Stat. Med. 1991;10:45–52. [PubMed]
119. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley; New York: 2004.
120. Stuart EA, Perry DF, Le H-N, Ialongo NS. Estimating intervention effects of prevention programs: accounting for noncompliance. Prev. Sci. 2008;9:288–98. [PMC free article] [PubMed] 121. Ten Have T, Normand S, Marcus S, Lavori P, Duan N, Brown C. Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatr. Ann. 2008;38(12) In press. [PMC free article] [PubMed] 122. Ten Have TR, Coyne J, Salzer M, Katz I. Research to improve the quality of care for depression: alternatives to the simple randomized clinical trial. Gen. Hosp. Psychiatry. 2003;25:115–23. [PubMed] 123. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004;60:684–93. [PubMed] 124. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics. 1998;54:251–64. [PubMed]
125. Todd S, Stallard N. A new clinical trial design combining Phase 2 and 3: sequential designs with treatment selection and a change of endpoint. Drug Inf. J. 2005;39:109–18.
126. UK Collab. ECMO Trial Group UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet. 1996;348:75–82. [PubMed] 127. Ulmer M, Robinaugh D, Friedberg JP, Lipsitz SR, Natarajan S. Usefulness of a run-in period to reduce drop-outs in a randomized controlled trial of a behavioral intervention. Contemp. Clin. Trials. 2008;29:705–10. [PubMed] 128. Victoria CG, Habicht J-P, Bryce J. Evidence-based public health: moving beyond randomized trials. Am. J. Public Health. 2004;94:400–5. [PubMed] 129. Volpp KG, Gurmankin Levy A, Asch DA, Berlin JA, Murphy JJ, et al. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemol. Biomark. Prev. 2006;15:12–18. [PubMed] 130. Wang L, Cui L. Seamless phase II/III combination study through response adaptive randomization. J. Biopharm. Stat. 2007;17:1177–87. [PubMed]
131. Ware JH. Investigating therapies of potentially great benefit: ECMO. Stat. Sci. 1989;4:298–306.
132. Ware JH. Investigating therapies of potentially great benefit: ECMO: Rejoinder. Stat. Sci. 1989;4:337–40.
133. Wei LJ. An application of an urn model to the design of sequential controlled clinical trials. J. Am. Stat. Assoc. 1978;73:559–63.
134. Wei LJ, Durham S. The randomized play-the-winner rule in medical trials. J. Am. Stat. Assoc. 1978;73:840–43.
135. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Wiley; New York: 1997.
136. Wolchik S, Sandler I, Weiss L, Winslow E. New beginnings: an empirically-based intervention program for divorced mothers to help children adjust to divorce. In: Briesmeister JM, Schaefer CE, editors. Handbook of Parent Training: Helping Parents Prevent and Solve Problem Behaviors. Wiley; Hoboken, NJ: 2007. pp. 25–66.
137. Wolchik SA, Sandler IN, Millsap RE, Plummer BA, Greene SM, et al. Six-year follow-up of preventive interventions for children of divorce: a randomized controlled trial. JAMA. 2002;288:1874–81. [PubMed] 138. Wood D, Halfon N, Donald-Sherbourne C, Mazel RM, Schuster M, et al. Increasing immunization rates among inner-city, African American children: a randomized trial of case management. JAMA. 1998;279:29–34. [PubMed] 139. Wyman PA, Brown CH, Inman J, Cross W, Schmeelk-Cone K, et al. Randomized trial of a gatekeeper program for suicide prevention: 1-year impact on secondary school staff. J. Consult. Clin. Psychol. 2008;76:104–15. [PMC free article] [PubMed]
140. Zelen M. Play the winner rule and the controlled clinical trial. J. Am. Stat. Assoc. 1969;64:131–46.
141. Zelen M. A new design for randomized clinical trials. N. Engl. J. Med. 1979;300:1242–45. [PubMed] 142. Zelen M. Randomized consent designs for clinical trials: an update. Stat. Med. 1990;9:645–56. [PubMed] 143. Zhang X, Cutter G. Bayesian interim analysis in clinical trials. Contemp. Clin. Trials. 2008;29:751–55. [PubMed] 144. Zohar S, Chevret S. Recent developments in adaptive designs for Phase I/II dose-finding studies. J. Biopharm. Stat. 2007;17:1071–83. [PubMed]